Does the PPAR-γ-activating property of telmisartan provide a benefit in clinical practice?
Authors:
Open Access
- 29 November 2012
- journal article
- research article
- Published by Springer Nature in Hypertension Research
- Vol. 36 (2) , 183
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Structural basis for telmisartan-mediated partial activation of PPAR gammaHypertension Research, 2012
- High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-γ Target Genes in Patients With the Metabolic SyndromeHypertension, 2011
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsNew England Journal of Medicine, 2008
- Effects of Telmisartan and Losartan on Insulin Resistance in Hypertensive Patients with Metabolic SyndromeHypertension Research, 2007
- The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjectsMetabolism, 2006
- Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeCardiovascular Diabetology, 2005
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertensionJournal of Human Hypertension, 2000